Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT, FRA:3N9) CEO Joey Wiley joined Proactive’s Stephen Gunnion to discuss the company's second-quarter results, which show a 35.9% rise in revenue year-on-year.
Wiley noting that it's the sixth consecutive quarter the company has reported positive EBITDA (core earnings) generation.
Given the strong performance year to date, Amryt has also raised its full-year 2021 revenue guidance to $210-$215 million.